Moderna acquired Japan's OriCiro to strengthen mRNA R&D technology.
(Reuters)
[Financial Channel/Comprehensive Report] U.S. drugmaker Moderna (Moderna) agreed on Wednesday (4th) to acquire OriCiro Genomics, a Japanese bio-innovative therapy research and development company, for US$85 million (approximately NT$2.6 billion) to enhance its mRNA Research and development technology.
OriCiro is working on the development and commercialization of a cell-free synthesis and amplification of a DNA molecule that makes mRNA.
OriCiro said its technology will be combined with Moderna's treatments and vaccines.
Moderna's mRNA technology has been used to develop a Wuhan pneumonia vaccine.
Please read on...
Moderna's experimental cancer vaccine, based on the technology, was shown to fight melanoma, a type of skin cancer.
Grasp the pulse of the economy with one hand I subscribe to Free Finance Youtube channel
Already added friends, thank you
Welcome to 【Free Finance】
feel good
Already liked it, thank you.
related news